Background/Purpose: Routine annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications. Influenza vaccine is recommended for all persons aged 6 months and older who do not have contraindications to vaccination. Despite those recommendations, there are no studies evaluating influenza vaccination influences on clinical manifestations in Behçet´s Disease (BD). Our objective is to evaluate short-term safety and efficacy of influenza A/California/7/2009/H1N1-like virus single vaccination and the potential deleterious effect of the vaccine in BD patients compared to healthy controls.
Methods: Eighty-five BD patients and 85 gender/age-matched healthy controls were evaluated before and 21-days after vaccination with unadjuvanted influenza A/H1N1-like virus regarding seroprotection/seroconversion, factor increase in geometric mean titre (FI-GMT), C-reactive-protein (CRP) levels and side effects. Brazilian BD Current Activity Form (BR-BDCAF) was used to assess BD activity.
Results: Seroconversion rate was significantly lower in BD patients compared to controls (69 vs. 83%, p=0.04). Similar rates of seroprotection (71 vs. 83%, p=0.06) and FI-GMT (p=0.96) were found. Interestingly, BD patients without seroconversion had significantly higher mean BR-BDCAF scores (6.0 ±4.1 vs. 3.8 ±4.3, p=0.009), with a significantly increased rate of active BD in this group (73 vs. 39%, p=0.003). Disease duration and glucocorticoid, immunosuppressors or TNF-blockers therapies did not affect seroconversion (p>0.05). Regarding side effects, patients had significantly increased rate of mild and transient reactions, such as fever (7 vs. 0%, p=0.02), headache, (27 vs. 12%, p=0.02), arthralgia (24 vs. 0.2%, p<0.001) and myalgia (25 vs. 9%, p=0.004). Moderate and severe side effects were not reported.
Conclusion: This is the first study to indicate appropriate influenza A/H1N1 vaccine safety and efficacy in BD, reinforcing its recommendation. Disease activity impaired humoral response to vaccination. Further studies are necessary to determine if a second dose would increase seroconversion rates in these patients.
Disclosure:
L. L. Prado,
None;
C. G. S. Saad,
Federico Foundation,
2;
J. C. B. Moraes,
None;
A. C. M. Ribeiro,
None;
N. E. Aikawa,
None;
C. A. Silva,
None;
C. G. Schainberg,
None;
P. D. Sampaio-Barros,
None;
A. R. Precioso,
None;
M. A. Ishida,
None;
E. Bonfa,
CNPQ #301411/2009-3,
2,
Federico Foundation,
2;
C. Goncalves,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-activity-an-important-factor-for-immunogenicity-of-unadjuvanted-influenza-ah1n1-vaccine/